Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$55.43

0.38 (0.69%)

17:22
10/09/16
10/09
17:22
10/09/16
17:22

Bristol-Myers reports safety data for Phase 1 lirilumab studies

Bristol-Myers Squibb and Innate Pharma announced safety data for two Phase I studies conducted by Bristol-Myers testing lirilumab in combination with nivolumab or ipilimumab, respectively, in patients with advanced refractory solid tumors. Lirilumab was licensed by Innate to Bristol-Myers. The safety profile of the combination of lirilumab and nivolumab therapy was similar to that of nivolumab monotherapy, with the exception of an increased frequency of low grade infusion-related reactions in patients treated with the lirilumab combinations. These reactions were clinically managed and similar to those seen with lirilumab alone. In the limited population -- 22 patients -- studied for the combination of lirilumab and ipilimumab, there did not appear to be additional safety concerns compared to ipilimumab monotherapy. Specifically, the CA223-001 study of lirilumab-nivolumab, no dose-limiting toxicities were reported. The overall rate of treatment-related adverse events was reported as 71.7 percent and the rate of Grade 1-2 TRAEs was 56.6 percent. The rate of Grade 3-4 TRAEs was 15.1 percent. Discontinuations due to TRAEs occurred in 7.5 percent, with only treatment related pneumonitis and diarrhea occurring in more than one patient. In the CA223-002 trial of lirilumab-ipilimumab, the overall rate of treatment-related adverse events was reported as 68.2 percent and the rate of Grade 1-2 TRAEs was 59.1 percent. The rate of Grade 3-4 TRAEs was 9.1 percent and included erythematous rash and pruritus and hypopituitarism. This study is complete and the combination of lirilumab with ipilimumab is no longer being evaluated. "Based on these data, further evaluation of lirilumab in combination with nivolumab is warranted. Efficacy data from the lirilumab and nivolumab combination study will be reported separately," the company said.

  • 09

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

BMY Bristol-Myers
$55.43

0.38 (0.69%)

09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/20/16
SBSH
09/20/16
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $75 at Citi
In a research note titled "Brace Yourself. Attractive Valuation but No Near-Term Respite.," Citi analyst Andrew Baum lowered his price target for shares of Bristol-Myers Squibb to $70 from $75. The analyst lowered his earnings forecasts by up to 8% to reflect the "limited supportive data" in the non-small cell lung cancer indication. Baum keeps a Buy rating on the shares as he views the valuation as attractive. He points out, however, the near-term news-flow is likely to be negative.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.

TODAY'S FREE FLY STORIES

02:35
01/24/18
01/24
02:35
01/24/18
02:35
General news
FX Update: The dollar has come under fresh pressure »

FX Update: The dollar has…

01:55
01/24/18
01/24
01:55
01/24/18
01:55
General news
FX Action: USD-JPY tumbled below 110.00 »

FX Action: USD-JPY…

NVS

Novartis

$87.21

0.21 (0.24%)

, CMCSA

Comcast

$42.44

-0.45 (-1.05%)

20:25
01/23/18
01/23
20:25
01/23/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

NVS

Novartis

$87.21

0.21 (0.24%)

CMCSA

Comcast

$42.44

-0.45 (-1.05%)

GE

General Electric

$16.89

0.72 (4.45%)

UTX

United Technologies

$136.03

0.82 (0.61%)

ABT

Abbott

$59.23

-0.34 (-0.57%)

GD

General Dynamics

$207.48

-0.72 (-0.35%)

ITW

Illinois Tool Works

$173.06

-0.33 (-0.19%)

NSC

Norfolk Southern

$151.66

0.19 (0.13%)

BHGE

Baker Hughes

$35.82

0.27 (0.76%)

PGR

Progressive

$57.05

-1.17 (-2.01%)

RCL

Royal Caribbean

$127.22

-1.48 (-1.15%)

SWK

Stanley Black & Decker

$173.89

-1.34 (-0.76%)

ROK

Rockwell Automation

$204.69

0.76 (0.37%)

NTRS

Northern Trust

$106.89

-0.54 (-0.50%)

GWW

Grainger

$229.45

-0.41 (-0.18%)

ROL

Rollins

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 24

    Jan

  • 08

    Feb

  • 16

    Feb

  • 02

    Mar

  • 23

    Apr

  • 17

    May

CERS

Cerus

$4.33

0.14 (3.34%)

19:39
01/23/18
01/23
19:39
01/23/18
19:39
Conference/Events
Cerus to hold a pharmaceutical update conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 26

    Feb

XPER

Xperi

$22.85

0.35 (1.56%)

19:26
01/23/18
01/23
19:26
01/23/18
19:26
Conference/Events
Xperi to hold a conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDR

McDermott

$7.86

-0.1 (-1.26%)

19:14
01/23/18
01/23
19:14
01/23/18
19:14
Upgrade
McDermott rating change at KeyBanc »

McDermott upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDRBF

Bombardier

, ERJ

Embraer

$24.13

-0.34 (-1.39%)

19:08
01/23/18
01/23
19:08
01/23/18
19:08
Periodicals
Bombardier invokes Embraer in Boeing trade dispute, Globe and Mail says »

Bombardier (BDRBF) says…

BDRBF

Bombardier

ERJ

Embraer

$24.13

-0.34 (-1.39%)

BA

Boeing

$335.59

-2.41 (-0.71%)

DAL

Delta Air Lines

$59.93

-0.2 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 21

    Feb

GSBC

Great Southern Bancorp

$52.00

0.45 (0.87%)

19:01
01/23/18
01/23
19:01
01/23/18
19:01
Earnings
Great Southern Bancorp reports preliminary Q4 EPS 86c, consnesus 83c »

Reports preliminary Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

UUUU

Energy Fuels

$1.72

0.035 (2.08%)

18:48
01/23/18
01/23
18:48
01/23/18
18:48
Hot Stocks
Energy Fuels names Mark S. Chalmers president and CEO »

Energy Fuels announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

18:15
01/23/18
01/23
18:15
01/23/18
18:15
General news
Breaking General news story  »

Chicago Federal Reserve…

RBS

RBS

$8.46

-0.02 (-0.24%)

18:10
01/23/18
01/23
18:10
01/23/18
18:10
Periodicals
RBS plans to leave London headquarters by end of 2019, Reuters reports »

The Royal Bank of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TROX

Tronox

$21.88

0.07 (0.32%)

18:09
01/23/18
01/23
18:09
01/23/18
18:09
Hot Stocks
Tronox files lawsuit to prevent FTC from blocking proposed Cristal acquisition »

Tronox filed a lawsuit in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBNK

United Financial

$17.92

-0.03 (-0.17%)

18:00
01/23/18
01/23
18:00
01/23/18
18:00
Hot Stocks
United Financial reports Q4 provision for loan losses $2.3M »

Reports Q4 provision for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

UBNK

United Financial

$17.92

-0.03 (-0.17%)

17:59
01/23/18
01/23
17:59
01/23/18
17:59
Earnings
United Financial reports Q4 EPS with items 19c, consensus 30c »

Companies must recognize…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

SPY

SPDR S&P 500 ETF Trust

$283.29

0.6 (0.21%)

, SPX

S&P 500

17:55
01/23/18
01/23
17:55
01/23/18
17:55
General news
Breaking General news story on SPDR S&P 500 ETF Trust, S&P 500 »

Senate confirms Jerome…

SPY

SPDR S&P 500 ETF Trust

$283.29

0.6 (0.21%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

17:55
01/23/18
01/23
17:55
01/23/18
17:55
Conference/Events
Federal Reserve Bank of Chicago President participates in a discussion »

Chicago Federal Reserve…

HESM

Hess Midstream Partners

$21.75

0.45 (2.11%)

17:46
01/23/18
01/23
17:46
01/23/18
17:46
Hot Stocks
Hess Midstream Partners raises quarterly dividend 3.6% to 32.2c per unit »

The distribution will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 26

    Feb

GWB

Great Western

$44.29

0.53 (1.21%)

17:33
01/23/18
01/23
17:33
01/23/18
17:33
Hot Stocks
Great Western announces financial impact resulting from Tax Cuts and Jobs Act »

Great Western Bancorp,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

ARAY

Accuray

$5.20

0.05 (0.97%)

, TSS

TSYS

$83.92

0.17 (0.20%)

17:27
01/23/18
01/23
17:27
01/23/18
17:27
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

ARAY

Accuray

$5.20

0.05 (0.97%)

TSS

TSYS

$83.92

0.17 (0.20%)

CERS

Cerus

$4.33

0.14 (3.34%)

NTIP

Network-1 Technologies

$2.60

0.1 (4.00%)

GOOG

Alphabet

$1,169.97

14.16 (1.23%)

GOOGL

Alphabet Class A

$1,176.17

12.01 (1.03%)

QGEN

Qiagen

$33.55

0.5 (1.51%)

SIRI

SiriusXM

$5.68

0.03 (0.53%)

VLO

Valero

$98.69

-0.26 (-0.26%)

UAL

United Continental

$77.97

1.1 (1.43%)

NAVI

Navient

$13.44

-0.08 (-0.59%)

CREE

Cree

$35.02

-1.67 (-4.55%)

COF

Capital One

$105.71

0.22 (0.21%)

TXN

Texas Instruments

$119.89

0.45 (0.38%)

PBYI

Puma Biotechnology

$90.90

-3.05 (-3.25%)

SIGM

Sigma Designs

$7.00

0.025 (0.36%)

FPRX

Five Prime

$22.43

0.14 (0.63%)

RCKT

Rocket Pharmaceuticals

$15.19

1.92 (14.47%)

TK

Teekay Corp.

$10.74

0.05 (0.47%)

SBBP

Strongbridge Biopharma

$8.70

0.25 (2.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 26

    Feb

  • 28

    Feb

  • 18

    Mar

  • 21

    Mar

  • 24

    Jan

  • 24

    Jan

  • 25

    Jan

  • 26

    Jan

UAL

United Continental

$77.97

1.11 (1.44%)

17:25
01/23/18
01/23
17:25
01/23/18
17:25
Earnings
United Continental sees FY18 EPS $6.50-$8.50, consensus $6.97 »

Sees FY18 CapEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 21

    Mar

17:25
01/23/18
01/23
17:25
01/23/18
17:25
Conference/Events
The Chicago Council on Global Affairs to hold a panel discussion »

The Chicago Council on…

MULE

MuleSoft

$25.08

-0.31 (-1.22%)

17:21
01/23/18
01/23
17:21
01/23/18
17:21
Initiation
MuleSoft initiated at Nomura Instinet »

MuleSoft initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

MDB

MongoDB

$28.83

0.02 (0.07%)

17:19
01/23/18
01/23
17:19
01/23/18
17:19
Initiation
MongoDB initiated at Nomura Instinet »

MongoDB initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$77.97

1.1 (1.43%)

17:19
01/23/18
01/23
17:19
01/23/18
17:19
Hot Stocks
Breaking Hot Stocks news story on United Continental »

United sees FY19 and FY20…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 21

    Mar

UAL

United Continental

$77.97

1.1 (1.43%)

17:18
01/23/18
01/23
17:18
01/23/18
17:18
Hot Stocks
Breaking Hot Stocks news story on United Continental »

United sees FY18 CASM…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 21

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.